covid-19 vaccine news [ready to go] (2020) by Ayush vermauploaded:: 11:36:52pm 6 Aug 2020
Covid-19 vaccine news
[ready to go]
Coronavirus (Covid-19) vaccine latest update: Oxford-AstraZeneca vaccine production starts; US says 2 billion doses ‘ready to go’
Coronavirus (Covid-19) Vaccine Latest Update: AstraZeneca plans to roll out two billion doses of Covid-19 vaccine in September; human trials of Australian vaccine next month.
In latest developments, British pharma giant AstraZeneca, which is developing a vaccine in partnership with Oxford University, said it was “on track” to roll out up to two billion doses in September. Meanwhile, US also said that it had already produced two million vaccine doses that are “ready to go” if they “check out for safety”.
Astrazeneca announced this week it had struck agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, and the Serum Institute of India to double production capacity of the vaccine to two billion doses. The partnership with the Indian institute — one of the world’s largest vaccine manufacturers — will help supply it to a large number of low- and middle-income countries, AFP reported.
Oxford university began initial trials of its Covid-19 vaccine with hundreds of volunteers in April, and is now expanding them to 10,000 participants. Researchers announced this week they would start tests in mid-June in Brazil, the first country outside Britain to take part in the study.
The Cambridge-based firm has signed deals to produce 400 million doses for the US and 100 million for the UK if it is successful in human trials.
University of Queensland has partnered with pharmaceutical giant CSL to produce up to 100 million doses of a Covid-19 vaccine, which uses an innovative ‘molecular clamp technology’, by the end of next year, according to a ABC news report.
The home-grown vaccine has showed promising early results in the laboratory following which a deal has been struck between the University of Queensland (UQ), CSL and the Coalition for Epidemic Preparedness Innovations (CEPI) to fund human trials, which will start next month.
UQ researcher Paul Young said 120 people would be recruited for the first trial to test the vaccine’s safety and monitor the impact on the immune system. Next, a further 800 to 1,000 people will take part in the next stage of the vaccine trial.